InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

Core Insights - InMed Pharmaceuticals has strengthened its patent portfolio with the issuance of three U.S. patents, enhancing its intellectual property protection for drug candidates targeting high unmet medical needs [2][3]. Patent Portfolio Summary - The company now holds a total of 13 patent families covering new chemical entities, formulations, manufacturing methods, and methods of use [4]. - The newly granted patents include: - A method of use patent for topical cannabinoid formulations in treating epidermolysis bullosa, granted in the U.S., Australia, Japan, and Israel, with pending status in several other jurisdictions [3][4]. - A biosynthesis patent for manufacturing proprietary cannabinoid analogs, granted in the U.S. [3][4]. - An ocular drug delivery formulation patent, granted/allowed in the U.S., Europe, Australia, Japan, and India, with pending status in other jurisdictions [3][4]. Company Focus and Future Plans - InMed is committed to expanding its patent portfolio to protect its novel drug candidates and manufacturing methods, particularly for its INM-901 program targeting Alzheimer's disease and INM-089 for dry Age-related Macular Degeneration [4][5].